Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$6.52 USD
+0.38 (6.19%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.55 +0.03 (0.46%) 6:38 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 81 - 100 ( 222 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Update - Look to 4Q20 for Some Value Driving Data Readouts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ASCO - SY-5609 Anti-Tumor Activity Bodes Well for Phase 1 Data in 4Q20
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Update - Exciting 2020 Data Readouts Ahead, Sufficient Cash to 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are sending out a reminder about our 33rd Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Potential May Take Time to Reveal; Reit Neutral and Reducing PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q19 Update - Syros Reaffirms Previous Guidance for 2020 Data Releases
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Our Presenting Companies at the ROTH Conference and 2020 Catalyst Calendar
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q19 Financials; Awaiting Key Data Readouts in Q4:20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D